It should be taken into consideration that such an increased risk for hypoglycemia may be due to the simultaneous use of SGLT2 inhibitors and GLP-1-R agonists with other hypoglycemic agents, such as insulins or sulphonylureas, by some of the patients [59,60]. The gene discussed is SLC5A2; the disease is Hypoglycemia.